A case of vemurafenib-induced keratosis pilaris-like eruption

Dermatology Online Journal

Volumn 18, Issue 4, 2012, Pages 7-

  Wang, Connie M ^a   Fleming, Kristy F ^a   Hsu, Sylvia ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM LACTATE; VEMURAFENIB;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BLEEDING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; CREAM; DARIER DISEASE; FEMALE; GENE MUTATION; GINGIVA DISEASE; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; METASTATIC MELANOMA; PAPULE; POSITRON EMISSION TOMOGRAPHY; SKIN BIOPSY;

ADULT; ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; FEMALE; HUMANS; INDOLES; MELANOMA; NEOPLASM METASTASIS; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84864416620     PISSN: 10872108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Wellbrock C, Hurlstone A. BRAF as therapeutic target in melanoma. Biochem Pharmacol. 2010;80(5):561-567.[PubMed]
2. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.Abstract [PubMed]
3. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.[PubMed]
4. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.[PubMed]
5. Franck N, Barete S, Moguelet P, et al. Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenib. J Clin Oncol. 2010;28(31):e640-e642.[PubMed]
6. Arnault JP, Mateus C, Escudier B, et al. Skin tumors induced by sorafenib; Paradoxical RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53 and TGFBR1. Clin Cancer Res. 2011 Nov 17.[Epub ahead of print] [PubMed]
7. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464(7287):427-430.[PubMed]